Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies

Autor(es)

Boniche, Camila ^[1] ; Rossi, Suelen Andreia ^[1] ; Kischkel, Brenda ^[1] ; Barbalho, Filipe Vieira ^[1] ; D'Aurea Moura, Agata Nogueira ^[2] ; Nosanchuk, Joshua D. ^{[3, 4]} ; Travassos, Luiz R. ^[5] ; Taborda, Carlos Pelleschi ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Microbiol, Biomed Sci Inst, Sao Paulo 05508000 - Brazil

^[2] Univ Sao Paulo, Trop Med Inst, Dept Dermatol, Fac Med, Sao Paulo 05403000 - Brazil

^[3] Albert Einstein Coll Med, Dept Med, Div Infect Dis, New York, NY 10461 - USA

^[4] Albert Einstein Coll Med, Dept Microbiol & Immunol, Div Infect Dis, New York, NY 10461 - USA

^[5] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo 04021001 - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: JOURNAL OF FUNGI; v. 6, n. 1 MAR 2020.
• Citações Web of Science: 0

Resumo

The increasing incidence in systemic fungal infections in humans has increased focus for the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses are generally difficult to treat, as most occur in vulnerable individuals, with compromised innate and adaptive immune responses. Mortality rates in the setting of our current antifungal drugs remain excessively high. Moreover, systemic mycoses require prolonged durations of antifungal treatment and side effects frequently occur, particularly drug-induced liver and/or kidney injury. The use of monoclonal antibodies with or without concomitant administration of antifungal drugs emerges as a potentially efficient treatment modality to improve outcomes and reduce chemotherapy toxicities. In this review, we focus on the use of monoclonal antibodies with experimental evidence on the reduction of fungal burden and prolongation of survival in in vivo disease models. Presently, there are no licensed monoclonal antibodies for use in the treatment of systemic mycoses, although the potential of such a vaccine is very high as indicated by the substantial promising results from several experimental models. (AU)

• Processo FAPESP: 18/26402-1 - Prospecção de novos epítopos com potencial vacinal no controle da infecção experimental por Histoplasma capsulatum
• Beneficiário: Brenda Kischkel
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 16/08730-6 - Patogenicidade fúngica: efeito do tabagismo, resposta imune e a modulação vacinal na paracoccidioidomicose e na histoplasmose
• Beneficiário: Carlos Pelleschi Taborda
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/25780-0 - Apresentação por células dendríticas humanas de peptídeos com capacidade vacinal e prospecção de antígenos pan-fúngicos na paracoccidioidomicose
• Beneficiário: Suélen Andreia Rossi
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado